



### ***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

1 to 77 (Cancelled).

78. (Previously presented) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2.

79. (Previously presented) The method of claim 78 which is *in vitro*.

80. (Previously presented) The method of claim 78 which is *in vivo*.

81. (Previously presented) The method of claim 78, wherein the polypeptide is glycosylated.

82. (Previously presented) The method of claim 78, wherein said antibody or fragment thereof is polyclonal.

83. (Previously presented) The method of claim 78, wherein said antibody or fragment thereof is monoclonal.

84. (Currently amended) The method of claim 78, wherein said antibody or fragment thereof is selected from the group consisting of:

(a) ~~a chimeric antibody;~~

(a) ~~(b)~~ a Fab fragment; and

(b) ~~(e)~~ a F(ab')<sub>2</sub> fragment.

85. (Previously presented) The method of claim 78, wherein said antibody or fragment thereof is labeled.

86. (Previously presented) The method of claim 85, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

87. (Previously presented) The method of claim 78, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

88. (Previously presented) The method of claim 78, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

89. (Previously presented) The method of claim 78, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

90. (Previously presented) The method of claim 89, wherein said compound is TRAIL.

91. (Previously presented) The method of claim 89, wherein said compound is a chemotherapeutic drug.

92 to 133. (Cancelled)

134. (Previously presented) A method of treating cancer, comprising administering to a patient an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2, wherein said

antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

135. (Previously presented) The method of claim 134, wherein the polypeptide is glycosylated.

136. (Previously presented) The method of claim 134, wherein said antibody or fragment thereof is polyclonal.

137. (Previously presented) The method of claim 134, wherein said antibody or fragment thereof is monoclonal.

138. (Currently amended) The method of claim 134, wherein said antibody or fragment thereof is selected from the group consisting of:

~~(a) — a chimeric antibody;~~

(a) ~~(b)~~ a Fab fragment; and

(b) ~~(c)~~ a F(ab')<sub>2</sub> fragment.

139. (Previously presented) The method of claim 134, wherein said antibody or fragment thereof is labeled.

140. (Previously presented) The method of claim 139, wherein said label is selected from the group consisting of:

(a) an enzyme;

(b) a fluorescent label; and

(c) a radioisotope.

141. (Previously presented) The method of claim 134, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

142. (Previously presented) The method of claim 134, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

143. (Previously presented) The method of claim 134, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

144. (Previously presented) The method of claim 143, wherein said compound is TRAIL.

145. (Previously presented) The method of claim 143, wherein said compound is a chemotherapeutic drug.

146 to 181. (Cancelled).

182. (Previously presented) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2.

183. (Previously presented) The method of claim 182 which is *in vitro*.

184. (Previously presented) The method of claim 182 which is *in vivo*.

185. (Previously presented) The method of claim 182, wherein the polypeptide is glycosylated.

186. (Previously presented) The method of claim 182, wherein said antibody or fragment thereof is polyclonal.

187. (Previously presented) The method of claim 182, wherein said antibody or fragment thereof is monoclonal.

188. (Currently amended) The method of claim 182, wherein said antibody or fragment thereof is selected from the group consisting of:

~~(a) a chimeric antibody;~~

(a) ~~(b)~~ a Fab fragment; and

(b) ~~(e)~~ a F(ab')<sub>2</sub> fragment.

189. (Previously presented) The method of claim 182, wherein said antibody or fragment thereof is labeled.

190. (Previously presented) The method of claim 189, wherein said label is selected from the group consisting of:

(a) an enzyme;

(b) a fluorescent label; and

(c) a radioisotope.

191. (Previously presented) The method of claim 182, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

192. (Previously presented) The method of claim 182, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

193. (Previously presented) The method of claim 182, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

(a) TRAIL; and

(b) a chemotherapeutic drug.

194. (Previously presented) The method of claim 193, wherein said compound is TRAIL.

195. (Previously presented) The method of claim 193, wherein said compound is a chemotherapeutic drug.

196 to 237. (Cancelled).

238. (Previously presented) A method of treating cancer, comprising administering to a patient an antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

239. (Previously presented) The method of claim 238, wherein the polypeptide is glycosylated.

240. (Previously presented) The method of claim 238, wherein said antibody or fragment thereof is polyclonal.

241. (Previously presented) The method of claim 238, wherein said antibody or fragment thereof is monoclonal.

242. (Currently amended) The method of claim 238, wherein said antibody or fragment thereof is selected from the group consisting of:

~~(a) — a chimeric antibody;~~

(a) ~~(b)~~ a Fab fragment; and

(b) ~~(c)~~ a F(ab')<sub>2</sub> fragment.

243. (Previously presented) The method of claim 238, wherein said antibody or fragment thereof is labeled.

244. (Previously presented) The method of claim 243, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

245. (Previously presented) The method of claim 238, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

246. (Previously presented) The method of claim 238, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

247. (Previously presented) The method of claim 238, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

248. (Previously presented) The method of claim 247, wherein said compound is TRAIL.

249. (Previously presented) The method of claim 247, wherein said compound is a chemotherapeutic drug.

250 to 285. (Cancelled).